William Waldegrave - GW Pharmaceuticals Non-Executive Independent Director
Director
The Rt. Hon. Lord William Arthur Waldegrave is NonExecutive Independent Director of the Company. He served as a Conservative Member of the British Parliament from 1979 to 1997 including sixteen years as a Government Minister, of which seven years were as a Cabinet Minister . Educated at Oxford University and Harvard, before entering Parliament he worked in the Cabinet Office in Whitehall as Political Secretary to Prime Minister Edward Heath and for GEC Ltd. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University and a Distinguished Fellow of All Souls College, Oxford and an Honorary Fellow of Corporationrations Christi College, Oxford. From 19982008 he worked at Deutsche Kleinwort Benson and UBS. From 19982015, he served as Chairman of Biotechnology Growth Trust plc. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation, and a former Chairman of the National Museum of Science and Industry. since 2017.
| Tenure | 7 years |
| Phone | (44) 1223 235667 |
| Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Lynch | Kontoor Brands | 44 | |
| Luis Bermdez | BBB Foods | 53 | |
| Juliana Chugg | Kontoor Brands | 52 | |
| Javier Suarez | BBB Foods | 47 | |
| Marcia Santos | Marfrig Global Foods | N/A | |
| Jodi Butts | Canada Goose Holdings | 48 | |
| Jose Miron | Marfrig Global Foods | 52 | |
| David McDonald | Marfrig Global Foods | N/A | |
| Antonio Maciel | Marfrig Global Foods | N/A | |
| Mark Schiller | Kontoor Brands | 59 | |
| John Davison | Canada Goose Holdings | 62 | |
| Katherine Blair | Skechers USA | 50 | |
| Carlos Langoni | Marfrig Global Foods | 73 | |
| Richard Siskind | Skechers USA | 74 | |
| Alejandro Davila | BBB Foods | 46 | |
| Diego Apalategui | BBB Foods | 47 | |
| Stephen Gunn | Canada Goose Holdings | 65 | |
| JeanMarc Huet | Canada Goose Holdings | 51 | |
| Joshua Bekenstein | Canada Goose Holdings | 61 | |
| Rodrigo Marcal | Marfrig Global Foods | N/A | |
| Herculano Alves | Marfrig Global Foods | 62 | |
Management Performance
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Waldegrave, Non-Executive Independent Director | ||
| Christopher Tovey, COO, Executive Director | ||
| Thomas Lynch, Non-Executive Independent Director | ||
| Catherine Mackey, Non-Executive Independent Director | ||
| Justin Gover, CEO, Director | ||
| Geoffrey Guy, Executive Chairman of the Board | ||
| James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
| Julian Gangolli, Executive Director | ||
| Alicia Secor, Non-Executive Independent Director | ||
| Adam George, CFO, Company Secretary, Director | ||
| Cabot Brown, Non-Executive Independent Director | ||
| Stephen Wright, Research & Development Director, Executive Director | ||
| Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |